HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Dec. 6, 2005--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that Cohen Independent Research Group has issued a “Buy” recommendation in newly written research coverage on the Company. The report is available at www.cohenresearch.com as well as from First Call, Bloomberg, and other leading providers. The base case assumption of the report values NYMX at $7.20 per share with a target of $10.00. The 19 page report states, “We continue to rate Nymox Pharmaceutical Corp a “Buy”.”
